Related Experiment Video

Updated: May 22, 2026

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

A primer for achieving glycemic control in the cardiac surgical patient

Marie E McDonnell1, Sara M Alexanian, Lynn White

  • 1Section of Endocrinology, Diabetes, Nutrition and Weight Management, the Boston University, School of Medicine, Boston, Massachusetts, USA. marie.mcdonnell@bmc.org

Journal of Cardiac Surgery
|May 30, 2012
PubMed

Insights

Maintaining blood glucose below 180 mg/dL improves survival for patients undergoing coronary artery bypass graft (CABG) surgery. This review outlines a perioperative glycemic control strategy for all CABG patients, aligning with SCIP and STS guidelines.

Area of Science:

  • Cardiology
  • Endocrinology
  • Surgical Care

Background:

  • Glycemic control is crucial for patients with diabetes mellitus undergoing coronary artery bypass graft (CABG) surgery.
  • Maintaining blood glucose below 180 mg/dL is associated with reduced morbidity and improved long-term survival post-CABG.
  • Current guidelines from the Surgical Care Improvement Project (SCIP) and Society of Thoracic Surgeons (STS) emphasize perioperative glycemic management.

Purpose of the Study:

  • To present a comprehensive management strategy for achieving optimal perioperative glycemic control.
  • To ensure compliance with established SCIP and STS guidelines for all patients undergoing CABG surgery.
  • To address glycemic management in both diabetic and non-diabetic patients during the perioperative period.

Main Methods:

  • Review of current literature and guidelines on perioperative glycemic control.
  • Development of a standardized management strategy for blood glucose monitoring and intervention.
  • Application of the strategy to all patients undergoing CABG, irrespective of diabetes status.

Main Results:

  • A structured approach to perioperative glycemic control can be effectively implemented.
  • Adherence to the strategy facilitates compliance with SCIP and STS guidelines.
  • Consistent glycemic management benefits all patients undergoing CABG surgery.

Conclusions:

  • Perioperative glycemic control is a critical component of optimizing outcomes for CABG patients.
  • The presented strategy provides a framework for achieving recommended blood glucose levels.
  • Implementing this strategy can enhance patient survival and reduce complications following CABG surgery.

More Related Videos

Hyperglycemic Clamp and Hypoglycemic Clamp in Conscious Mice07:35

Hyperglycemic Clamp and Hypoglycemic Clamp in Conscious Mice

Published on: January 26, 2024

Sleeve Gastrectomy in Mice using Surgical Clips05:16

Sleeve Gastrectomy in Mice using Surgical Clips

Published on: November 14, 2020

Related Concept Videos

Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
Cardiomyopathy VII: Pre and Post Operative Nursing Management01:28

Cardiomyopathy VII: Pre and Post Operative Nursing Management

Patients with hypertrophic cardiomyopathy (HCM) and left ventricular outflow tract (LVOT) obstruction who remain symptomatic despite optimal medical therapy may undergo a septal myectomy (Morrow procedure). This procedure involves excising a portion of the hypertrophied septum below the aortic valve using a heart-lung machine to improve blood flow through the LVOT. Effective preoperative and postoperative nursing management ensures successful patient outcomes, minimizes complications, and...
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Diabetic Ketoacidosis l: Introduction01:25

Diabetic Ketoacidosis l: Introduction

DefinitionDiabetic ketoacidosis (DKA) is an acute, life-threatening complication of diabetes mellitus, characterized by a triad of hyperglycemia (blood glucose >250 mg/dL), ketonemia or ketonuria, and metabolic acidosis (arterial pH <7.30 and serum bicarbonate <18 mEq/L). It results from insulin deficiency combined with elevated levels of counterregulatory hormones—glucagon, catecholamines, cortisol, and growth hormone—leading to increased lipolysis, hepatic ketone production, and...